Tag Archives: kidney-first diabetes therapy

  As the burden of diabetic kidney disease (DKD) continues to grow, so does the urgency for early, evidence-based interventions. The concept of kidney protection diabetes is shifting—clinicians are now encouraged to initiate therapy before substantial kidney function loss occurs. Two major drug classes—SGLT2 inhibitors and GLP‑1 receptor agonists—are leading …

Read More »